Takeda Takes Back Rare Epilepsy Drug in Revised Deal with Ovid

Takeda Pharmaceutical has revised its collaboration deal with US biotech Ovid Therapeutics, regaining global rights for soticlestat, a treatment for rare pediatric epilepsies that has been jointly developed by the two companies. The Japanese drug juggernaut said on March 3...read more